Brown & Brown, Inc. · NYSE:BRO

Brown & Brown — Metabolic Health Summer Series (July 2023)

30 slides from Brown & Brown's conference presentation, Jul 12, 2023

  1. Slide 1: Metabolic Health Summer Series

    Metabolic Health Summer Series An Inside Look at Diabetes and Weight Loss Medications July 12, 2023 Presented By: Kelly Polinski, MPH, CWPM Austin Morgan, PharmD, BCACP, CDCES Andrea Grande, RPh

  2. Slide 2: Today’s Presenters

    Today’s Presenters OPENING KEYNOTE EMPLOYER REMARKS SPEAKER PERSPECTIVE Kelly Polinski, Austin Morgan, Andrea Grande, RPh MPH, CWPM PharmD, BCACP, CDCES Principal, Pharmacy, National Population Health Lead Clinical Pharmacist III – Brown & Brown Consultant, Brown & Brown Development and Training, Tr

  3. Slide 3: Disclaimer

    Disclaimer Brown & Brown, Inc. and all its affiliates, do not provide legal, regulatory or tax guidance, or advice. If legal advice counsel or representation is needed, the services of a legal professional should be sought. The information in this document is intended to provide a general overview o

  4. Slide 4: Presentation Agenda

    Presentation Agenda 1 Metabolic Health and Obesity 2 Metabolic Syndrome 3 GLP-1 and Incretin Medications 4 Employer Considerations BROW N & BROW N | 4

  5. Slide 5: Metabolic Health and Obesity

    01 Metabolic Health and Obesity

  6. Slide 6: Metabolic Health

    C O N T R I B U T O R S T O M E TA B O L I C H E A LT H Metabolic Health A healthy metabolism means that a body can digest and absorb nutrients from food without unhealthy spikes in blood sugar, blood fat, inflammation and insulin. Every individual has their own metabolic health informed by age, sex

  7. Slide 7: Obesity Prevalence and Costs

    Obesity Prevalence and Costs Prevalence of Obesity in U.S. Adults* 45 From 1975 to 2016, the global Percentage of Adult Population obesity rate has nearly tripled; almost 50% of Americans are considered obese. 35 The CDC estimates that the extra medical expenses associated with obesity exceeds $173

  8. Slide 8: Obesity Treatments

    Obesity Treatments Due to limited efficacy on While bariatric surgery Until recently, anti-obesity The newest drugs to market, weight loss with lifestyle continues to be effective, it medications, namely appetite called the GLP-1s, are not and behavior intervention is not always an optimal or suppre

  9. Slide 9: Tria Health

    ©) tria HEALTH’ smarter. medication. management.

  10. Slide 10: Metabolic Syndrome

    02, Metabolic Syndrome

  11. Slide 11: Metabolic Syndrome

    Metabolic Syndrome1 ABDOMINAL OBESITY HYPERTENSION Excess body fat around the waist and trunk and waist Also known as “High Blood Pressure,” is a sign that the heart is circumference show a strong association with other metabolic working harder to pump blood through narrowing and less elastic condit

  12. Slide 12: Metabolic Syndrome

    Metabolic Syndrome1 ABDOMINAL OBESITY HYPERTENSION Excess body fat around the waist and trunk and waist Also known as “High Blood Pressure,” is a sign that the heart is circumference show a strong association with other metabolic working harder to pump blood through narrowing and less elastic condit

  13. Slide 13: How to Manage?

    Metabolic Syndrome1 ABDOMINAL OBESITY HYPERTENSION Excess body fat around the waist and trunk and waist Also known as “High Blood Pressure,” is a sign that the heart is circumference show a strong association with other metabolic working harder to pump blood through narrowing and less elastic condit

  14. Slide 14: GLP-1 and Incretin Medications

    03 GLP-1 and Incretin Medications

  15. Slide 15: Public Interest Is Spiking

    Public Interest Is Spiking U.S. Google Trends 100 • GLP1s and GIP/GLP1 classes 90 of medications are approved to treat diabetes or obesity, 80 and both are effective weight 70 loss agents. 60 50 • Semaglutide 40 (Ozempic®/Wegovy®) and 30 tirzepatide (Mounjaro™) are most popular, but there are 20 oth

  16. Slide 16: GLP-1s Have Significant Impact on Weight Loss

    GLP-1s Have Significant Impact on Weight Loss • Wegovy (semaglutide) weight loss clinical trials1 » Between 10% and 17.5% body weight lost » Weight gain or up to 5% weight loss with placebo • Diabetes medications in same classes also showed positive effects on weight • Mounjaro (tirzepatide) weight

  17. Slide 17: A Word of Caution

    A Word of Caution FDA Warning • Ongoing Ozempic and Wegovy shortage • Compounded semaglutide1 » Different salt forms of active ingredient » Not shown safe or effective in humans Reason for Concern What • Unregulated to do? • Risk for side effects or contamination 1. Research Center for Drug Evaluati

  18. Slide 18: What Are the Similarities and Differences?

    What Are the Similarities and Differences? Active Ingredient Brand Name Product FDA Approval Semaglutide Ozempic® Diabetes • Same active ingredients and mechanisms Semaglutide Wegovy® Obesity • Different doses and clinical trial design Liraglutide Victoza® Diabetes • Tirzepatide (Mounjaro) is a ‘dua

  19. Slide 19: The Biggest Differences? Insurance Coverage

    The Biggest Differences? Insurance Coverage Injectable Incretin Mimetics Active Ingredient Brand Name Product FDA Approval Semaglutide Ozempic® Diabetes Semaglutide Wegovy® Obesity • Diabetes approvals = tiered copays Liraglutide Victoza® Diabetes • Weight management Liraglutide Saxenda® Obesity app

  20. Slide 20: The Impact of Increased Media Attention

    The Impact of Increased Media Attention Pros Cons • Highlights that overweight and obesity • Increased off-label use has led to shortages of medication for are chronic health conditions that are those who need it to manage diabetes.2 treatable with effective drugs.1 • Supply issues may also require

  21. Slide 21: Using Medications for Weight Loss

    Using Medications for Weight Loss Pros Cons • Increasing acceptance of obesity as a • High cost and limited insurance coverage chronic condition • Prior authorization criteria for the drugs only approved for diabetes • High effectiveness • Not everyone responds to treatment • Ease of use • Side effe

  22. Slide 22: Using Medications for Weight Loss

    Using Medications for Weight Loss CASE 1 • Patient interested in weight loss during chronic condition management appointment • The pharmacist referred patient to an in-house health coach with Tria’s weight management program and, after comprehensive medication/disease state review, recommended semag

  23. Slide 23: Using Medications for Weight Loss

    Using Medications for Weight Loss CASE 2 • Patient with T2DM started tirzepatide (Mounjaro) for A1c and weight reduction • Weight, BMI and A1c at initiation: 330 lbs., 53.3 kg/m2 and 6.9%, respectively • Minimal lifestyle change on top of medication • After 2 titrations to tirzepatide 7.5 mg, A1c de

  24. Slide 24: Looking Forward to a Full Pipeline

    Looking Forward to a Full Pipeline 01 02 03 04 05 CLINICAL RESEARCH DEVELOPMENT M A N U FA C T U R I N G R E G U L AT O R Y STUDIES Retatrutide Oral, Non-Peptide Combined Mechanisms Oral High-Dose The Big Question “triple-G” GLP-1 RA Cagrilintide plus Semaglutide4 End stage outcomes agonist1 Orforgl

  25. Slide 25: Employer Considerations

    04 Employer Considerations

  26. Slide 26: Employer Benefit Coverage

    Employer Benefit Coverage E VA L U AT I N G T H E P R O S A N D C O N S O F E M P L O Y E R C O V E R A G E O F A N T I - O B E S I T Y D R U G S Pros Cons • May help employee recruitment and retention • Medications are costly with no current guidelines to end treatment • Likely weight reduction may

  27. Slide 27: Employer Benefit Coverage

    Employer Benefit Coverage O T H E R C O N S I D E R AT I O N S BMI is not always an accurate measure of health. Too high or too low is not an ironclad guarantee that a chronic disease will develop; it’s an important piece of information in the context of evaluating the whole person.1 Evaluate PBM fo

  28. Slide 28: How We Can Help

    How We Can Help The Brown & Brown Population Health & Well-Being team takes a proactive and comprehensive approach to help prevent metabolic conditions from developing and helping those with existing Health care costs for those with metabolic conditions to manage their health. syndrome are on averag

  29. Slide 29: The Metabolic Summer Series Continues…

    The Metabolic Summer Series Continues… The Future of Metabolic Health: Weight-Loss Medication Benefits for Positive Impact on Your Population and Your Bottom Line Wednesday, August 16, 2023 1:00 – 2:00 PM CDT Speakers • Tim Church, M.D., Ph.D., M.P.H., Chief Medical Officer, Wondr Health • Louise Sh

  30. Slide 30: How Brown & Brown Can Help

    How Brown & Brown Can Help Connect with your local Brown & Brown representative or visit us on the web to learn more about our population health and employee benefits services. V I S I T B B R O W N . C O M / C O N TA C T  Brown & Brown, Inc. and all its affiliates, do not provide legal, regulatory

Brown & Brown — Metabolic Health Summer Series (July 2023) on 6ix